ESTUDIO DE LA SUSCEPTIBILIDAD A VANCOMICINA DE CEPAS DE Staphyloccus spp., AISLADAS DEL HOSPITAL ANTONIO PATRICIO DE ALCALÁ, CUMANÁ, ESTADO SUCRE :::VANCOMYCIN SUSCEPTIBILITY STUDY OF Staphylococcus spp. STRAINS ISOLATED FROM ANTONIO PATRICIO DE ALCALÁ HOSPITAL, CUMANÁ, SUCRE STATE

Lorena Abadia-Patiño, Sarai Acuña, Isangel Manosalva

Resumen


De todas las cepas de Staphylocccus aureus almacenadas en el cepario del Laboratorio de Resistencia Bacteriana del IIBCAUDO, se analizaron 14 para determinar la disminución de susceptibilidad a vancomicina. Sesenta y cuatro por ciento de las cepas crecieron en el cribado de vancomicina. La CMI a vancomicina de las cepas estuvo entre 1 y 2 mg/L por microdilución. La CMI por dilución en agar fue entre 2 y 4 mg/L. La CMB de las cepas fue de 2 y 4 mg/L. Ninguna cepa fue tolerante. No se detectaron cepas hVISA por PAP-AUC. Se recomienda realizar el cribado de vancomicina en cepas aisladas de sitios estériles. 

Palabras clave: Glicopéptidos, bacteriemias, endocarditis, VISA.

Abstract

From all strains of Staphylocccus aureus stored in the Bacterial Resistance Laboratory ceparium of IIBCAUDO, fourteen strains were analyzed to determine the decreasing susceptibility to vancomycin. Sixty four percent of strains grew on vancomycin screening. MIC vancomycins were between 1 and 2 mg/L by microdilution method. MIC agar dilutions were 2 and 4 mg/L. MBC were 2 and 4 mg/L. None of the strain was tolerant. No hVISA strains with PAP-AUC method was detected. We suggest vancomycin screening for all strains isolated from sterile sites. 

Key words: Glycopeptides, bacterimias, endocarditis, VISA.


Referencias


ACUÑA S, SÁNCHEZ E, ABADÍA-PATIÑO L. 2014. Tipificación de la meticilino resistencia en cepas de Staphylococcus spp. Hospital Universitario “Antonio Patricio de Alcalá Cumaná. Estado Sucre, Venezuela. Rev. Soc. Venez. Microbiol. 34(1):4-9.

BHATEJA P, MATHUR T, PANDYA M, FATMA T, RATTAN A. 2005. Detection of vancomycin resistant Staphylococcus aureus: a comparative study of three different phenotypic screening methods. Indian J. Med. Microbiol. 23(1):522-55.

CASTELLANO M, PEROZO A, GONZÁLEZ A. 2012. Evaluación de la susceptibilidad a glicopéptidos en cepas de Staphylococcus aureus resistentes a oxacilina. Kasmera. 40(1):7-15.

CLSI (CLINICAL AND LABORATORY STANDARDS INSTITUTE). 1999. Document M26-A. Methods for Determining Bactericidal Activity of Antimicrobial Agents, Approved Guideline, Wayne, PA, USA.

CLSI (CLINICAL AND LABORATORY STANDARDS INSTITUTE). 2011. Performance standards for antimicrobial disk and dilution susceptibility testing; 21thinformational supplement, M100-S21.Wayne, Pa, USA.

EL SOLH N, DAVI M, MORVAN A, DAMON H, MARTY M. 2003. Characteristics of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility or resistance to glycopeptides. J. Antimicrob. Chemother. 52(4):691-694.

NUNES AP, SCHUENCK RP, BASTOS CC, MAGNANINI MM, LONG JB, IORIO NL, DOS SANTOS KR. 2007. Heterogeneous resistance to vancomycin and teicoplanin among Staphylococcus spp. isolated from bacteremia. Braz. J. Infect. Dis. 11(3):345-50.

FRENCH G. 2006. Bactericidal agents in the treatment of MRSA infections the potential role of daptomycin. J. Antimicrob. Chemother. 58(6):1107-1117.

HIRAMATSU K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1(3):147-155.

HIRAMATSU K, HANAKI H, INO T, YABUTA K, OGURI T, TENOVER F. 1997. Methicillin-resistant Staphylococcus aureus clinical strain wit reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40(1):135-136.

HOLMES R, JORGENSEN J. 2008. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob. Agents Chemother. 52(2):757-760.

HOWDEN B, DAVIES J, JOHNSON P, STINEAR T, GRAYSON M. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23(1):99-139.

KOHNER P, PATEL R, UHL J. 1997. Comparison of agar dilution, broth microdilution, E-test, disk diffusion, and automated vitek methods for testing susceptibilities of Enterococcus spp. to vancomycin. J. Clin. Microbiol. 35(12):3258-3263.

LIU C, CHAMBERS H. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: Epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47(10):3040-3045.

MA X, WANG E, LIU Y, LUO E. 2011. Antibiotic susceptibility of coagulase-negative staphylococci (CoNS): emergence of teicoplanin non- susceptible CoNS strains with inducible resistance to vancomycin. J. Med. Microbiol. 60(11):1661-1668.

MACLAYTON D, SUDA K, COVAL K, YORK C, GAREY K. 2006. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 µg/ml and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin. Ther. 28(8):1208-1216.

MAOR Y, RAHAV G, BELAUSOV N, BEN-DAVID D, SMOLLAN G, KELLER N. 2007. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J. Clin. Microbiol. 45(5):1511-1514.

PALAZZO I, ARAUJO M, DARINI A. 2005. First report of vancomycin-resistant staphylococci isolated from healthy carriers in Brazil. J. Clin. Microbiol. 43(1):179-185.

SADER H, FRITSCHE T, JONES R. 2006. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob. Agents Chemother. 50(7):2330-2336.

SADER H, JONES R, ROSSI K, RYBAK M. 2009. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J. Antimicrob. Chemother. 64(5):1024-1028.

SAKOULAS G, BRODER P, SCHENTAG J, FORREST A, MOELLERING R, ELIOPOULOS G. 2004. Relationship of CMI and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42(6):2398-2402.

SIEVERT DM, BOULTON ML, STOLTMAN G, JOHNSON D, STOBIERSKI MGG, DOWNES FP. 2002. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb. Mortal. Wkly. Rep. 51(26):565-567

SWENSON J, ANDERSON K, LONSWAY D. 2009. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin intermediate Staphylococcus aureus. J. Clin. Microbiol. 47(7):2013-2017.

TRACZEWSKI M, KATZ D, STEENBERGEN J, BROWN S. 2009. Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007. Antimicrob. Agents Chemother. 53(5):1735-1738.

WALSH T, HOWE R. 2002. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu. Rev. Microbiol. 56:657-675.

WALSH T, BOLMSTROM A, QWARNSTROM A. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39(7):2439-2444.

WANG JL, WANG JT, SHENG W, CHEN Y, CHANG S. 2010. Nosocomial methicillin- resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC: 2 mg/L, by the broth microdilution method. BMC Infect. Dis. 10:159.


Texto completo:

PDF

Referencias



Enlaces refback

  • No hay ningún enlace refback.
';



Licencia Creative Commons” style=
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.